Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

<p><strong>Background</strong> The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to es...

Full description

Bibliographic Details
Main Authors:	Butler, CC, Hobbs, FDR, Gbinigie, OA, Rahman, NM, Hayward, G, Richards, DB, Dorward, J, Lowe, DM, Standing, JF, Breuer, J, Khoo, S, Petrou, S, Hood, K, Nguyen-Van-Tam, JS, Patel, MG, Saville, BR, Marion, J, Ogburn, E, Allen, J, Rutter, H, Francis, N, Thomas, NPB, Evans, P, Dobson, M, Madden, T-A, Holmes, J, Harris, V, Png, ME, Lown, M, van Hecke, O, Detry, MA, Saunders, CT, Fitzgerald, M, Berry, NS, Mwandigha, L, Galal, U, Mort, S, Jani, BD, Hart, ND, Ahmed, H, Butler, D, McKenna, M, Chalk, J, Lavallee, L, Hadley, E, Cureton, L, Benysek, M, Andersson, M, Coates, M, Barrett, S, Bateman, C, Davies, JC, Raymundo-Wood, I, Ustianowski, A, Carson-Stevens, A, Yu, L-M, Little, P
Other Authors:	PANORAMIC Trial Collaborative Group
Format:	Journal article
Language:	English
Published:	Elsevier 2022

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Similar Items